Exact Sciences Corp
NASDAQ:EXAS
Exact Sciences Corp
NASDAQ:EXAS
Price:
1 865.09
USD
1 677.8%
Market Closed
Market Cap:
$356B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Exact Sciences Corp
NASDAQ:EXAS
|
US |
|
N
|
Nomura Real Estate Master Fund Inc
TSE:3462
|
JP |
|
I
|
Innovative Medical Management Co Ltd
SZSE:002173
|
CN |
|
S
|
Sanbo Hospital Management Group Ltd
SZSE:301293
|
CN |
|
RH
NYSE:RH
|
US |
|
F
|
Fujitec Co Ltd
TSE:6406
|
JP |
|
Amarin Corporation PLC
NASDAQ:AMRN
|
IE |
|
Thunderbird Entertainment Group Inc
XTSX:TBRD
|
CA |
|
E
|
Envictus International Holdings Ltd
SGX:BQD
|
SG |
|
Lar Espana Real Estate SOCIMI SA
MAD:LRE
|
ES |
|
S
|
SDI Group PLC
LSE:SDI
|
UK |
|
Beijing Kingsoft Office Software Inc
SSE:688111
|
CN |
|
C
|
China Youran Dairy Group Ltd
HKEX:9858
|
CN |
|
Travis Perkins PLC
LSE:TPK
|
UK |
|
Hansol Chemical Co Ltd
KRX:014680
|
KR |
|
WSP Global Inc
TSX:WSP
|
CA |
Multiples-Based Value
The Multiples-Based Value of one
EXAS
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 1 865.09 USD,
Exact Sciences Corp
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
EXAS Multiples-Based Value
LOCKED
Multiples Across Competitors
EXAS Competitors Multiples
Exact Sciences Corp Competitors
Exact Sciences Corp Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
355.9B USD | 109.6 | -1 710.6 | 15 890.6 | -1 794.3 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
366.3B USD | 6 | 87.5 | 14.5 | 20.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
190.8B USD | 5.2 | 24.7 | 14.3 | 14.3 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
171.6B USD | 5.8 | 20.2 | 12.6 | 15.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.6B USD | 9.6 | 29.2 | 22 | 23 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.2B USD | 5.5 | 17.6 | 13 | 14.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
68B AUD | 3.2 | 35.2 | 11.6 | 14.6 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
43.5B USD | 11.7 | 138.9 | 77.7 | 86.3 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
